Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; levonorgestrel alters cervical mucus and endometrial lining to prevent fertilization and implantation.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
One tablet containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol (or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo or ethinyl estradiol 0.01 mg alone. For extended-cycle regimens, dosing may be continuous for up to 84 days.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Levonorgestrel: ~25 hours; Ethinyl estradiol: ~13 hours. Steady-state achieved within 5-7 days; clinical efficacy maintained by daily dosing.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Levonorgestrel: 45% renal, 32% fecal; Ethinyl estradiol: 40% renal, 60% fecal. Both undergo enterohepatic recirculation.
Category D/X
Category D/X
Progestin + Estrogen
Estrogen